Pfizer chief has ‘courage’ to pursue deals

Speculation over $17bn cash pile has grown as rivals consolidate

Rachel Brough, Senior Scientific Officer at the Institute of Cancer Research works in a laboratory, testing new drugs, at the ICR. Photographed for UK News
©Charlie Bibby

Clinical trial data should be made public

Drug companies and regulators are adopting transparency too slowly

France shrugs off the smoking ban

The country that gave us Gitanes may soon enact strict antismoking laws, writes Adam Thomson

Hikma boosts US generics with Roxane buy

Jordanian group to pay a mixture of cash and shares to Boehringer

23 Mar 2015 - Parsippany, New Jersey - Brent Saunders, Actavis CEO photographed in the New Jersey Office
©Sara Hylton

Allergan paves way for new mega deal

Chief hints at ‘transformational’ purchase after generics sale

Pharma M&A: portfolio theory

Even after a $40bn deal, the pharma sector remains unsettled

Upbeat Reckitt raises growth forecasts

Profits rise 10% with Europe and N America markets more stable

Mylan plunges after Teva abandons bid

Shares drop as Israeli group pursues rival Allergan deal

Biological markers and longevity

Tracking of vital signs takes a new tack

Philips buoyed by US healthcare recovery

Chief warns over the impact of macroeconomic slowdown

Allergan on the move with $41bn Teva deal

Israeli group’s deal with Botox maker ends pursuit of Mylan

NHS outsourcing deal loses 1,000 jobs

Capita plans cuts when it takes on a £1bn contract in September

Bioven seeks IPO to market Cuban drug

Improved relations with US set to open up Cuban life sciences

Companies diary: July 27 — July 31

Diary commentary from FT reporters

Teva closes in on Allergan’s generics unit

Deal likely to end Israeli company’s pursuit of Mylan

GlaxoSmithKline: dose of reality

Mosquirix approval is good but pharma group needs more than that

Week in Review, July 25

Credit Suisse’s strong results; Eli Lilly and Lockheed also in the news

Anthem agrees to buy Cigna for $48bn

Deal will create the biggest health insurer in the US

First malaria vaccine gets a green light

But critics question whether Mosquirix is effective enough

Shire still on the hunt for acquisitions

UK biotech company reports 9% sales rise


More FT Twitter accounts